Adenosine Kinase Deficiency (ADK Deficiency)

Adenosine kinase deficiency is a very rare, inherited metabolic disease. The body normally uses an enzyme called adenosine kinase (ADK) to change adenosine into AMP so cells can keep adenosine at safe levels and keep methylation chemistry working well. When ADK does not work because of changes (mutations) in the ADK gene, adenosine builds up. This pushes another enzyme, S-adenosylhomocysteine hydrolase, backwards. As a result, S-adenosylhomocysteine (SAH) and often S-adenosylmethionine (SAM) rise and the SAM:SAH ratio falls. These changes disturb the methionine cycle, leading to high methionine in blood (hypermethioninemia), liver problems, developmental delay, and seizures in many children. It is autosomal recessive (a child inherits one faulty copy from each parent). PubMed Central+1

Adenosine kinase deficiency is a very rare, inherited metabolic disease. A change (mutation) in the ADK gene makes the body’s adenosine kinase enzyme work poorly. This enzyme normally adds a phosphate group to adenosine and helps keep adenosine, AMP/ATP, and the methionine cycle in balance. When the enzyme is weak, adenosine builds up, and the methionine pathway becomes “backed up.” This causes high blood methionine, build-up of SAM and SAH, and stress on the liver and brain. Babies often show jaundice and liver issues early, and many children later have developmental delay and seizures. ADK deficiency is autosomal recessive (both gene copies are affected). The condition is identified by blood/urine tests and gene testing, and careful diet (low methionine) can help some patients. PubMed CentralPubMed+1Orpha.net

Other names

This condition is also called “Hypermethioninemia encephalopathy due to adenosine kinase deficiency,” “ADK hypermethioninemia,” “ADK deficiency,” and, in older sources, “Mental retardation, autosomal recessive 8 (MRT8)”. Online catalogs list it under OMIM #614300 and Orphanet ORDO:289290. These names all point to the same disorder where mutations in the ADK gene cause persistent high methionine with raised SAM and SAH, and symptoms from the brain and liver. GARD Information CenterMalaCardsMouse Genome Informatics

Types

There is no single official subtype system yet, but reports show a few useful patterns that doctors often see. Think of them as clinical forms along a spectrum:

1. Neonatal/early-infantile hepatic-neurologic form. Babies present in the first weeks–months with prolonged jaundice, cholestasis, enlarged liver, low blood sugar due to hyperinsulinism, and later hypotonia and developmental delay. Many also develop seizures. Methionine, SAM and SAH are high; homocysteine is normal or slightly raised. PubMed CentralFrontiers

2. Childhood neurologic-predominant form. Some children have milder or transient early liver disease, but show global developmental delay, epilepsy, and dysmorphic facial features as the main concerns. ScienceDirect

3. Transient severe liver disease with later improvement. A few infants have marked early cholestasis or even liver failure that improves over time, while neurodevelopmental issues become clearer later. PubMed

4. Late-recognized/low-residual-activity form. Rarely, diagnosis is made years later, including after liver transplant, when re-review of old samples or genetic testing reveals ADK deficiency. Frontiers

Causes

Core cause 

1. Biallelic pathogenic variants in the ADK gene. The disease happens when both ADK gene copies carry harmful changes (missense, nonsense, frameshift, splice, or small deletions), reducing or abolishing ADK enzyme activity. PubMedScienceDirect

Variant-level mechanisms 

1. Missense variants change one amino acid and can weaken the enzyme’s shape or activity. ScienceDirect
2. Nonsense variants create a stop signal, making a short, non-working enzyme. ScienceDirect
3. Frameshift variants shift the reading frame and usually destroy function. ScienceDirect
4. Splice variants disrupt normal RNA splicing, so the enzyme is mis-built. ScienceDirect
5. Small exonic deletions/insertions remove or add coding material, breaking the protein. ScienceDirect

Pathway consequences

1. Adenosine accumulation because ADK cannot convert adenosine to AMP. PubMed Central
2. SAH build-up and low SAM:SAH ratio, inhibiting methylation reactions. PubMed Central
3. Hypermethioninemia due to methionine-cycle disruption. PubMed Central
4. Impaired transmethylation in liver and brain, which harms cell signaling and gene regulation. Frontiers
5. Secondary liver injury (cholestasis, enzyme elevation) from metabolic stress. ScienceDirect
6. Neuronal hyperexcitability and plasticity changes, contributing to seizures and cognitive issues. The Journal of Neuroscience

Genetic/epidemiologic context 

1. Autosomal recessive inheritance (parents are usually healthy carriers). PubMed
2. Parental consanguinity increases the chance both copies carry the same rare variant (risk factor, not a separate disease cause). PubMed

Triggers/Modifiers 

1. High methionine intake in infancy (protein-heavy feeds) may push methionine higher in an already impaired cycle. PubMed Central
2. Intercurrent infections can unmask metabolic stress and worsen liver tests or seizures. (General metabolic disease principle noted in case series.) ScienceDirect
3. Fasting or poor intake may provoke hypoglycemia in infants with hyperinsulinism. PubMed Central
4. Certain medications that influence adenosine signaling could, in theory, aggravate symptoms; careful specialist oversight is advised (inference consistent with the central role of adenosine). PubMed Central
5. Overall methylation burden (rapid growth periods) may expose deficits when SAM:SAH balance is low. IUBMB Journal
6. Individual residual ADK activity (some variants leave small activity) likely shapes how severe or mild the course is. ScienceDirect

Symptoms and signs

1. Prolonged newborn jaundice and cholestasis. Yellow eyes/skin that last longer than usual, pale stools, dark urine—due to impaired bile flow. PubMed Central

2. Liver enlargement and abnormal liver enzymes. Doctors feel a big liver and blood tests show high ALT/AST or GGT. ScienceDirect

3. Low blood sugar with high insulin (hyperinsulinism). Babies may be sleepy, shaky, or have seizures from low glucose. PubMed Central

4. Poor feeding and failure to thrive. Trouble gaining weight and growing as expected. ResearchGate

5. Generalized hypotonia. “Floppy” tone and delayed motor milestones. PubMed

6. Global developmental delay. Slower language, motor, and cognitive progress. PubMed

7. Epileptic seizures. Events vary from subtle infantile episodes to more obvious convulsions. ScienceDirect

8. Facial dysmorphism. Features can include frontal bossing, wide-set eyes, macrocephaly, or depressed nasal bridge. GARD Information Center

9. Respiratory distress in early life. Sometimes the first sign in the newborn period. PubMed

10. Sepsis-like episodes. Infants may look very ill with fevers and poor perfusion, even when infection is not proven. PubMed

11. Irritability and sleep problems. Common non-specific neurologic behaviors in metabolic encephalopathy (reported across series). ScienceDirect

12. Learning difficulties. Persist into school years if support and control of metabolic imbalance are delayed. ScienceDirect

13. Cardiac defects (some cases). Such as pulmonary stenosis or septal defects have been noted in a minority. GARD Information Center

14. Stroke or vascular tortuosity (very rare). Reported in isolated cases. ResearchGate

15. Variable course over time. Liver signs may improve, while neurodevelopmental needs continue; severity differs widely between children. Frontiers

Diagnostic tests

A) Physical examination

1. General exam and growth charting. The clinician checks weight, length, and head size over time. Poor growth or macrocephaly can point to a metabolic or neurologic disorder. GARD Information Center

2. Skin and sclera for jaundice. Ongoing yellow color after the first weeks suggests cholestasis and prompts metabolic testing. PubMed Central

3. Abdominal palpation for hepatomegaly. Feeling an enlarged liver supports liver involvement common in ADK deficiency. ScienceDirect

4. Neurologic tone and reflexes. Low tone, delayed postural reactions, or abnormal reflex patterns fit the reported neurodevelopmental picture. PubMed

5. Dysmorphology screening. A careful look at facial structure (frontal bossing, hypertelorism, nasal bridge) adds diagnostic clues. GARD Information Center

B) Manual/bedside developmental tests

6. Standardized developmental screening (e.g., Bayley/DENVER methods). Hands-on tasks assess cognition, language, and motor function; delays suggest metabolic or genetic causes and justify lab testing. (General approach; fits the phenotype.) ScienceDirect

7. Feeding assessment and suck-swallow evaluation. Identifies coordination problems that contribute to failure to thrive in infancy. (Linked to hypotonia and encephalopathy.) PubMed

8. Bedside hypoglycemia checks during symptoms. Quick finger-stick glucose when the infant seems lethargic or jittery can catch hyperinsulinemic hypoglycemia. PubMed Central

C) Laboratory and pathological tests

9. Plasma amino acids (quantitative). Methionine is persistently high; this is a key screening clue in ADK deficiency and often the first abnormality seen. PubMed

10. SAM and SAH levels (specialized labs). Both are typically elevated; the SAM:SAH ratio is low, indicating methylation stress. PubMed Central

11. Total homocysteine. Usually normal or only mildly high, which helps separate ADK deficiency from other hypermethioninemias. PubMed Central

12. Liver panel. ALT/AST, GGT, bilirubin (direct) are often abnormal with cholestasis in infants. ScienceDirect

13. Glucose with concurrent insulin and ketones. Supports hyperinsulinemic hypoglycemia when low glucose coexists with inappropriately normal/high insulin and low ketones. PubMed Central

14. Plasma/urine adenosine (specialized). May show elevated adenosine, backing the enzymatic block. (Used in research/tertiary centers.) PubMed Central

15. ADK enzyme activity (fibroblasts/lymphocytes). Direct functional proof of low enzyme activity when available. PubMed Central

16. Molecular genetic testing of ADK. Sequencing (including copy-number analysis) shows biallelic variants and confirms diagnosis; also enables family testing. PubMed

D) Electrodiagnostic tests

17. Electroencephalogram (EEG). Looks for epileptic activity and background slowing in children with seizures or developmental delay. (Seizures are common.) ScienceDirect

18. Brain functional studies as indicated (e.g., evoked potentials). If hearing or vision concerns are present, these tests evaluate neural pathways, complementing structural imaging. (General neurometabolic practice.) ScienceDirect

E) Imaging tests

19. Abdominal ultrasound (± elastography). Shows liver size, biliary tree, and signs of cholestasis or evolving fibrosis, and helps follow recovery or progression. ScienceDirect

20. Brain MRI (± MR spectroscopy). May be normal or show non-specific changes (e.g., delayed myelination); used to evaluate unexplained seizures/developmental delay and to rule out other causes. (Reported across case series; mechanistic animal/human data link ADK changes to synaptic dysfunction.) The Journal of NeuroscienceScienceDirect

Non-pharmacological treatments

Physiotherapy & rehabilitation 

1. Early developmental therapy: guided play to build head control, rolling, sitting; improves neuroplasticity when started early.

2. Neurodevelopmental treatment (NDT/Bobath): handling and postural control techniques to normalize tone and movement patterns.

3. Positioning & 24-hour posture care: supports chest expansion, reduces reflux/aspiration, and protects joints.

4. Tummy time / prone play: strengthens shoulder girdle and neck; better feeding posture.

5. Range-of-motion stretching: prevents contractures in hypotonia evolving to spasticity.

6. Task-specific motor training: step-by-step practice of sitting, standing, transfers.

7. Balance & vestibular training: improves steadiness and fall prevention.

8. Strengthening (proximal/core): graded resistance with therapy bands and play tasks; supports gait quality.

9. Gait training (walkers/parallel bars): builds endurance and safety for ambulation.

10. Orthotic management (AFOs/SMOs): aligns foot/ankle for stable stance and energy-efficient walking.

11. Respiratory physio (airway clearance / breathing control) during infections to reduce deconditioning.

12. Oromotor/feeding therapy: improves suck–swallow–breath coordination; safer textures.

13. Sensory integration strategies: regulate arousal and attention to support learning.

14. Hydrotherapy (aquatic): warm water reduces tone, enables symmetrical movements.

15. Home exercise & caregiver coaching: daily micro-sessions lock in clinic gains.

Mind-body, education, and systems supports 

1. Nutritional counseling for low-methionine diet (see diet section): core disease-modifying strategy. Wiley Online Library+1
2. Augmentative & alternative communication (AAC): picture boards or speech-generating devices to reduce frustration and improve participation.
3. Special education / Individualized Education Plan (IEP): structured goals, therapies embedded in school day.
4. Parent training & psychosocial support: stress management, problem-solving around feeding and sleep; improves adherence and outcomes.
5. Sleep hygiene program: consistent routines reduce seizure risk and daytime fatigue.
6. Behavioral therapy / positive behavior supports: builds communication and adaptive behavior.
7. Assistive technology & environmental modifications: seating systems, bathing supports, safe home layout.
8. Routine vaccination & infection prevention: reduces metabolic stress episodes.
9. Genetic counseling for the family: explains autosomal recessive inheritance, carrier testing, and future pregnancy options.
10. (Research horizon) Gene therapy concept (liver-directed ADK gene delivery) — not clinically available yet; discussed as a future possibility based on enzyme biology. NCBI

---

Drug treatments

Important: dosing must be set by your clinician using age, weight, liver status, and local protocols. Below are typical roles/mechanisms used in practice for ADK-related problems, drawn from reports and standard pediatric/hepatic/epilepsy care. The only disease-modifying measure with published benefit is methionine restriction (diet). Wiley Online Library+1

1. Ursodeoxycholic acid (UDCA) — cholestasis support.
   Class: Bile acid; choleretic. Purpose: Improve bile flow, relieve cholestasis/itch. Mechanism: Replaces toxic bile acids, protects hepatocytes, promotes bile secretion. Typical use: 10–20 mg/kg/day in divided doses (clinician-set). Side effects: Diarrhea, rarely worsening in certain cholestatic disorders; monitor LFTs. (Used widely in pediatric cholestasis; applied in ADK-related cholestasis.) PubMed

2. Fat-soluble vitamins (A, D, E, K) — deficiency prevention in cholestasis.
   Class: Vitamins. Purpose: Maintain vision/bone/coagulation/antioxidant function. Mechanism: Replace malabsorbed vitamins due to poor bile flow. Time/dose: Dosing and formulation (water-miscible) per level-guided pediatric protocols. Side effects: Hypervitaminosis risk if over-supplemented; monitor levels/INR. PubMed

3. Vitamin K (phytonadione) — coagulation support.
   Class: Vitamin; Purpose: Correct prolonged INR in cholestasis. Mechanism: Restores γ-carboxylation of clotting factors. Dose/time: Per pediatric hepatology protocol (oral/IM/IV). Side effects: Rare injection reactions; monitor INR. PubMed

4. Levetiracetam — first-line antiseizure.
   Class: ASM. Purpose: Control seizures without hepatic metabolism burden. Mechanism: Binds SV2A; stabilizes synaptic release. Dose: Weight-based; start low, titrate. Side effects: Somnolence, irritability; adjust if behavioral change. (Common in metabolic epilepsies.) PubMed

5. Clobazam or Lamotrigine — adjunct seizure control.
   Class: Benzodiazepine / sodium-channel modulator. Purpose: Add-on for refractory seizures. Mechanisms: GABA-A allosteric modulation / membrane stabilization. Dose/time: Titrated by specialist. Side effects: Sedation (clobazam); rash with lamotrigine (slow titration). PubMed

6. Avoid/Use with caution: Valproate in infants with liver disease.
   Reason: Hepatotoxic risk may be higher; choose alternatives where possible. PubMed

7. Baclofen — spasticity management (if present).
   Class: GABA-B agonist. Purpose: Reduce muscle stiffness, improve comfort. Mechanism: Lowers excitatory neurotransmission in spinal cord. Dose: Weight-based; slow titration. Side effects: Sedation, hypotonia; taper to stop. (Symptomatic care.) — general neurorehab practice.

8. Melatonin — sleep regulation.
   Class: Hormone supplement. Purpose: Improve sleep architecture; indirectly lowers seizure risk. Dose: Pediatric clinician-guided. Side effects: Morning grogginess, vivid dreams. (Supportive neuro care.)

9. Lactulose ± Rifaximin — hepatic encephalopathy (when indicated).
   Class: Osmotic laxative / gut antibiotic. Purpose: Reduce ammonia-producing flora. Mechanism: Acidifies colon (traps NH3), decreases ammonia load. Dose: Per hepatic protocol to 2–3 soft stools/day. Side effects: Bloating/diarrhea (lactulose). (Used if clinical encephalopathy occurs.) — standard hepatology practice.

10. Proton-pump inhibitor (e.g., omeprazole) — reflux affecting feeding.
    Purpose: Reduce acid exposure; protect esophagus; improve feeding comfort. Mechanism: Blocks gastric H+/K+ ATPase. Use: Shortest effective course. Side effects: Nutrient malabsorption risk with long use.

11. Ondansetron — antiemetic for vomiting episodes.
    Class: 5-HT3 antagonist. Purpose: Maintain hydration and caloric intake. Side effects: Constipation, QT prolongation risk; use per clinician.

12. Polyethylene glycol (PEG) — constipation (reduces metabolic stress from illness/poor intake).
    Dose: Weight-based; titrate to soft stools. Side effects: Bloating.

13. Carnitine (if deficient) — mitochondrial fatty-acid shuttle.
    Purpose: Support energy metabolism during illness; correct deficiency. Mechanism: Restores acyl-carnitine transport. Dose: Level-guided. Side effects: Fishy odor, GI upset. (Used only if labs suggest deficiency.)

14. N-Acetylcysteine (NAC) — antioxidant/hepatoprotective in acute liver injury.
    Class: Glutathione precursor. Purpose: Scavenges free radicals; supports hepatocyte defenses. Use: Acute settings per protocol. Side effects: Nausea, rare anaphylactoid reactions.

15. Comprehensive vaccination schedule (technically biologics, not “drugs,” but crucial) — reduces infection-triggered metabolic decompensation. (Follow national schedules.) PubMed

(Note: No evidence supports giving betaine or SAMe in ADK deficiency; methionine is typically elevated and homocysteine is often normal, so remethylation therapy used in other disorders may not help here.) Thieme

---

Dietary molecular supplements & medical foods

(Work with a metabolic dietitian; exact prescriptions depend on age, labs, and growth.)

1. Low-methionine medical formula (essential amino acid mixture without methionine) to lower methionine/SAM/SAH burden while meeting protein needs. Wiley Online Library+1

2. Measured natural protein from regular foods, carefully counted to keep methionine intake in target range. Wiley Online Library

3. Cystine/taurine as needed to balance sulfur amino acids while restricting methionine (dietitian-guided). Wiley Online Library

4. Medium-chain triglyceride (MCT) oil if fat malabsorption from cholestasis limits calories.

5. Vitamin A (water-miscible forms) with level monitoring.

6. Vitamin D (cholecalciferol) titrated to 25-OH D targets.

7. Vitamin E (tocopheryl polyethylene glycol succinate in cholestasis).

8. Vitamin K (as above) to maintain normal coagulation.

9. Zinc if deficient (supports growth, appetite, immunity).

10. Selenium if low (antioxidant enzyme cofactor). (Fat-soluble vitamin choices reflect pediatric cholestasis standards; methionine restriction has condition-specific evidence.) Wiley Online Library+1

---

Immunity-booster / regenerative / stem-cell” drugs

There are no approved immune-boosting, regenerative, or stem-cell drugs for ADK deficiency. Below are research or conceptual approaches; doses are not established and any use should only occur inside regulated clinical trials.

1. Liver-directed AAV-ADK gene therapy (concept). Replace functional ADK in hepatocytes to normalize adenosine/SAM/SAH. Status: Preclinical/concept, not available. NCBI

2. mRNA therapy for ADK (concept). Periodic lipid-nanoparticle delivery of ADK mRNA to the liver to restore enzyme transiently. Status: Experimental concept.

3. CRISPR base-editing or prime-editing (concept). Correct specific ADK variants in hepatocytes. Status: Research-stage only.

4. Autologous hepatocyte transplantation (investigational). Infuse corrected hepatocytes to support liver function. Status: Experimental for metabolic diseases; not established for ADK.

5. Mesenchymal stromal cell liver support (investigational). Paracrine/anti-inflammatory effects to support liver injury. Status: Research in other liver disorders; not standard.

6. Hepatoprotective antioxidant protocols during acute injury (e.g., N-acetylcysteine) — supportive rather than regenerative; dosing per acute care protocol. Status: Clinical supportive care. (Overall, the true disease-modifying evidence remains dietary methionine restriction.) Wiley Online Library+1

---

Surgeries / procedures

1. Liver transplantation — for end-stage liver failure or uncontrolled complications. Some ADK-deficient children who received transplant had long-term good liver function, but neurologic issues may persist, so transplant is reserved for clear hepatic indications. PubMed CentralPubMed

2. Gastrostomy tube (G-tube) — for severe feeding difficulty/aspiration risk; improves nutrition and medication delivery.

3. Vagus nerve stimulator (VNS) — for medically refractory epilepsy after specialist review.

4. Orthopedic procedures (e.g., tendon lengthening) — if contractures severely limit function despite therapy.

5. Liver biopsy (diagnostic) — when needed to clarify unexplained cholestasis early in the course. (Use has decreased as genetic testing expands.)

---

Prevention & long-term monitoring

1. Methionine-restricted diet with regular amino-acid, SAM/SAH, and growth monitoring. Wiley Online Library+1

2. Avoid high-methionine foods and unregulated supplements that add methyl load.

3. Routine immunizations (and flu/RSV strategies when indicated) to reduce infection stress.

4. Prompt treatment of infections and hydration during illness.

5. Regular liver checks: LFTs, INR, ultrasound/elastography.

6. Neurology follow-up for seizure control and sleep.

7. Fat-soluble vitamin monitoring in cholestasis.

8. Therapy services (PT/OT/SLP) started early and continued.

9. Medication review to avoid hepatotoxic agents when alternatives exist.

10. Family genetic counseling (carrier testing, prenatal options). Thieme

---

When to see a doctor

• Immediately / emergency: Worsening jaundice, very sleepy or hard to wake, new or prolonged seizures, bleeding/bruising, swollen abdomen, high fever with poor feeding, vomiting with dehydration, rapid breathing, or any sudden regression of skills.

• Soon (urgent clinic): Feeding refusal, persistent vomiting, lost medications, constipation not responding to home care, rising irritability or sleep reversal, new movement problems.

• Routine: Scheduled metabolic, liver, therapy, and neurology reviews; diet checks; lab monitoring guided by your team. (These red-flags align with reported hepatic/neurologic risks in ADK deficiency.) PubMed

---

Diet: what to eat and what to avoid

Core idea: keep methionine intake low but adequate for growth by using medical foods and measured amounts of natural protein.

Generally better choices (low methionine, dietitian-planned):

• Medical low-protein breads/pastas/rice products; many fruits; many vegetables; oils; sugars/honey in moderation for calories; plant milks/protein-free beverages; specialty low-protein medical foods.

• Carefully portioned lower-methionine plant proteins when permitted (dietitian will specify amounts). Wiley Online Library

Limit/avoid (high methionine):

• All meats (beef, chicken, fish), eggs, many cheeses (especially aged/hard), soy protein isolates, sesame, Brazil nuts, and high-protein supplements or “muscle” powders.

• Unsupervised use of methionine, choline, SAMe supplements. (The published guidance: treat symptomatic patients with methionine restriction; benefits have been reported including lab and MRI improvement.) Wiley Online Library+1

---

Frequently asked questions (FAQs)

1. How rare is ADK deficiency? Extremely rare; a few dozen patients have been reported worldwide in the literature to date. Frontiers

2. What gene is involved? The ADK gene, which makes the adenosine kinase enzyme. NCBI

3. How is it inherited? Autosomal recessive—both parents typically carry one non-working copy. PubMed

4. What are the earliest signs? Prolonged jaundice/cholestasis, poor feeding, low tone; later, developmental delay and seizures. PubMed

5. Is methionine always high? Usually elevated; homocysteine may be normal. SAM/SAH are often high. Thieme

6. What confirms the diagnosis? Gene testing for ADK variants; supportive labs (amino acids, SAM/SAH). Thieme

7. Does diet really help? Evidence and expert guidance support methionine restriction in symptomatic patients; reports show clinical and imaging improvements. Wiley Online Library+1

8. Will liver disease go away? It may improve in some; others can progress—rarely to liver failure; careful follow-up is essential. PubMed

9. Is liver transplant a cure? It can solve hepatic failure, but neurologic features may persist; transplant is considered only for strict hepatic indications. PubMed CentralPubMed

10. Are there specific drugs for ADK? No curative drug exists; management is supportive plus diet. Thieme

11. What about betaine or SAMe? They are not standard here; methionine is typically high, and homocysteine isn’t the main problem. Thieme

12. What does brain MRI show? Often delayed myelination/white-matter changes that can evolve. Semantic Scholar

13. Can children attend regular school? Many need special education and therapies; outcomes vary. PubMed

14. Should families get genetic counseling? Yes—for carrier testing and future pregnancy planning. Thieme

15. What’s the research horizon? Enzyme biology suggests potential for liver-directed gene therapy in the future, but none is available yet.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 08, 2025.

PDF Documents For This Disease Condition References